Fortunato Rocca Net Worth

Fortunato Rocca biography

Fortunato Ron Rocca serves as President, Chief Executive Officer and Director of the Company. Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus, a specialty pharmaceutical and diagnostic company which was acquired by Nestlé SA in 2011, where he was responsible for leading the commercial organization, strategic planning and implementation of projects designed to maximize brand sales. Prior to joining Prometheus, Mr. Rocca served as the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company and Janssen Pharmaceuticals, Inc., a pharmaceutical subsidiary of Johnson & Johnson. Mr. Rocca is currently a member of the board of directors for Interpace Biosciences, Inc. Mr. Rocca received a B.S. in Marketing and Personnel Management from Towson State University. Mr. Rocca’s extensive knowledge of our business, as well as his over 25 years of experience in the diagnostic and pharmaceutical industries, contributed to our Board's conclusion that he should serve as a director of our company.

What is the salary of Fortunato Rocca?

As the President a Chief Executive Officer and Director of Exagen Inc, the total compensation of Fortunato Rocca at Exagen Inc is $1,627,720. There are no executives at Exagen Inc getting paid more.

How old is Fortunato Rocca?

Fortunato Rocca is 58, he's been the President a Chief Executive Officer and Director of Exagen Inc since 2011. There are 7 older and 7 younger executives at Exagen Inc. The oldest executive at Exagen Inc is James Tullis, 72, who is the Independent Director.

What's Fortunato Rocca's mailing address?

Fortunato's mailing address filed with the SEC is C/O EXAGEN INC., 1261 LIBERTY WAY, VISTA, CA, 92081.

Insiders trading at Exagen Inc

Over the last 5 years, insiders at Exagen Inc have traded over $8,628,989 worth of Exagen Inc stock and bought 556,568 units worth $6,283,309 . The most active insiders traders include James L L Tullis, Bio Exagen, L.P.H.I.G. Gpii... a Jeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of $109,189. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth $77,570.

What does Exagen Inc do?

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Exagen Inc executives and stock owners

Exagen Inc executives and other stock owners filed with the SEC include:

• Fortunato Rocca,
  President, Chief Executive Officer and Director
• Fortunato Rocca,
  CEO, Pres & Director
• Kamal Adawi M.S., MBA,
  CFO & Corp. Sec.
• Dr. Debra Jeske Zack,
  Chief Medical Officer
• Kamal Adawi,
  Chief Financial Officer and Corporate Secretary
• Jeffrey Elliott,
  Independent Director
• Tina Nova,
  Independent Director
• Chet Burrell,
  Independent Director
• Brian Birk,
  Independent Chairman of the Board
• Bruce Robertson,
  Independent Director
• James Tullis,
  Independent Director
• Ebetuel Pallares,
  Independent Director
• Wendy Johnson,
  Independent Director
• Debra Zack,
  Chief Medical Officer
• Anja Kammesheidt,
  Chief Scientific Officer
• John Wegener,
  Sr. VP of Sales and Marketing
• Dr. Ming-Chou Lee Ph.D.,
  Chief Technology Officer
• Mark Hazeltine,
  Chief Operating Officer
• Frank Stokes,
  Director
• Scott D Kahn,
  Director
• Thierry Dervieux,
  Chief Scientific Officer
• James L Ltullis Growth Fund...,
  
• Bio Exagen, L.P.H.I.G. Gpii...,
  
• Dickerson Capital Focus Iii...,
  
• Holdings Limited Partnershi...,
  
• Co Investment Fund, L.P.Nms...,
  
• Paul Kim,
  Director
• Co Investment Fund, L.P.Sun...,
  
• Ana Hooker,
  Director
• John Aballi,
  President and CEO
• Mark Hazeltine,
  Chief Business Officer
• Jeffrey G. Black,
  Chief Financial Officer